Citizens Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $745
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $527 to $745.
Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $527 to $745.